162 related articles for article (PubMed ID: 34120367)
1. Diagnostic utility of the combined use of HNF4A and GATA3 in distinction between primary and metastatic breast and gastric carcinomas.
Saad DZ; Sidhom KF; Gadallah MF; Samir NA; Shakweer MM
APMIS; 2021 Sep; 129(9):548-555. PubMed ID: 34120367
[TBL] [Abstract][Full Text] [Related]
2. HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma.
van der Post RS; Bult P; Vogelaar IP; Ligtenberg MJ; Hoogerbrugge N; van Krieken JH
Virchows Arch; 2014 Jun; 464(6):673-9. PubMed ID: 24711169
[TBL] [Abstract][Full Text] [Related]
3. HNF4A expression as a potential diagnostic tool to discriminate primary gastric cancer from breast cancer metastasis in a Brazilian cohort.
Jucá PCFC; Corrêa S; Vignal GM; Accioly MTS; Lustosa SAS; Abdelhay E; Matos D
Diagn Pathol; 2017 Jun; 12(1):43. PubMed ID: 28583188
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte nuclear factor 4A expression discriminates gastric involvement by metastatic breast carcinomas from primary gastric adenocarcinomas.
Koyama T; Sekine S; Taniguchi H; Tsuda H; Ikegami M; Hano H; Kushima R
Hum Pathol; 2011 Nov; 42(11):1777-84. PubMed ID: 21733563
[TBL] [Abstract][Full Text] [Related]
5. GATA3 as a putative marker of breast cancer metastasis-A retrospective immunohistochemical study.
De Lara S; Parris TZ; Werner Rönnerman E; Helou K; Kovács A
Breast J; 2018 Mar; 24(2):184-188. PubMed ID: 28703335
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract][Full Text] [Related]
7. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
8. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
10. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
11. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
12. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
13. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of GATA3 Versus BRST2 for the Identification of Metastatic Breast Carcinoma in the Upper GI Tract: Which Performs Better?
Salagean D; Streutker C; Faragalla H; Jakate K
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):501-507. PubMed ID: 29629946
[TBL] [Abstract][Full Text] [Related]
16. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
[TBL] [Abstract][Full Text] [Related]
17. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
18. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
Boto A; Harigopal M
Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697
[TBL] [Abstract][Full Text] [Related]
19. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract.
O'Connell FP; Wang HH; Odze RD
Arch Pathol Lab Med; 2005 Mar; 129(3):338-47. PubMed ID: 15737028
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P
Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
